GSK plc with ticker code (GSK) now have 4 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price High/Low ranges between 63.75 and 35.5 with the average target price sitting at $44.36. Now with the previous closing price of $37.39 this now indicates there is a potential upside of 18.6%. It’s also worth noting that there is a 50 day moving average of $35.45 and the 200 moving average now moves to $35.01. The company has a market cap of $76,759m. Company Website: https://www.gsk.com
The potential market cap would be $91,068m based on the market consensus.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
The company has a dividend yield of 3.96% with the ex dividend date set at 23-2-2023 (DMY).
Other points of data to note are a P/E ratio of 13.78, revenue per share of 14.57 and a 6.57% return on assets.
